Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation

Enrico Maffini(Istituto di Ematologia di Bologna), Benedetto Bruno(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Moreno Festuccia(University of Turin), Alessandro Busca(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Lucia Brunello(University of Turin), Luisa Giaccone(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino)
Expert Review of Hematology
April 4, 2016
10.1080/17474086.2016.1174571
Cited by 57

Related Papers

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
|Blood|2003|407
Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
|Blood|2023|330
Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies
|JAMA|2011|323
Genetic PTX3 Deficiency and Aspergillosis in Stem-Cell Transplantation
|New England Journal of Medicine|2014|301